Search Results
Your search for Michael Pfreundschuh, MD matches 6 pages
Showing 1 - 6
Michael Pfreundschuh, MD, on Treating Lymphoid Malignancies in Children and Adults With the Same Protocols
Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, summarizes a session he chaired on this topic, which covered Burkitt’s lymphoma as well as lymphoblastic leukemia in children and adults.
Benefit of Extended Rituximab Exposure in Poor-Prognosis Elderly Patients With Diffuse Large B-Cell Lymphoma
In the phase II SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group reported in the Journal of Clinical Oncology, Pfreundschuh et al found that extended rituximab (Rituxan) exposure in patients aged > 60 years with poor-prognosis diffuse large B-cell lymphoma was...
Vitamin D Deficiency Worsens Response to Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
In a study reported in the Journal of Clinical Oncology, Bittenbring et al found that vitamin D deficiency was associated with poorer outcome in older patients receiving R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone) for diffuse large B-cell lymphoma...
No Apparent Benefit of Rituximab After Lymphoma-Directed Conditioning and Allogeneic Stem Cell Transplantation for Relapsed/Refractory Aggressive NHL
In an open-label phase II trial reported in The Lancet Oncology, Glass et al examined the strategy of adding rituximab (Rituxan) to standard prophylaxis for graft-vs-host disease after allogeneic stem cell transplantation in relapsed or refractory aggressive non-Hodgkin lymphoma. Rituximab did not...
Radiotherapy for Bulky Disease Added to R-CHOP Improves Outcome in Elderly Patients With Aggressive B-Cell Lymphoma
In an analysis reported in the Journal of Clinical Oncology, Held et al studied elderly patients with aggressive B-cell non-Hodgkin lymphoma and bulky disease in the most effective treatment arm of the RICOVER-60 trial, which included radiotherapy. The investigators compared outcomes ...
Addition of Rituximab Does Not Improve Outcome in Aggressive B-Cell Lymphoma With Skeletal Involvement, but Radiotherapy Benefit Found
In a retrospective analysis of German High-Grade Non-Hodgkin Lymphoma Study Group trials reported in Journal of Clinical Oncology, Gerhard Held, MD, of Saarland University Medical School in Homburg, and colleagues assessed the impact of rituximab (Rituxan) and radiotherapy on outcome in patients...
